News Search Results
Oct 01, 2025, 02:00 ET Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Sep 30, 2025, 08:30 ET Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
designed to rejuvenate somatic cells and restore tissue function, creating opportunities for a long list of regenerative therapies in dermatology, ophthalmology, immunology, osteoarthritis, muscle health and diseases like amyotrophic lateral sclerosis ("ALS"). Importantly, as part
More news about: Klotho Neurosciences, Inc.
Sep 30, 2025, 05:00 ET Restoring children's vision, reducing inequalities: NTC renews partnership with Sightsavers Italia
2025 /PRNewswire/ -- On the occasion of World Sight Day, NTC, an Italian pharmaceutical company with a strong vocation for innovation in ophthalmology, proudly announces the renewal of its collaboration with Sightsavers Italia ETS, an international organization that for 75 years has been dedicated
More news about: NTC Srl
Sep 29, 2025, 10:56 ET Parker Waichman LLP Files Lawsuit on behalf of Georgia Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority
More news about: Parker Waichman LLP
Sep 29, 2025, 10:00 ET Unifeye Vision Partners Announces CEO Transition: Appoints Mark Garvin as Chief Executive Officer to Succeed Martin Rash
physician-led ambulatory surgery center operator with integrated practice management services focused on ophthalmology. The company delivers comprehensive management and support services to ophthalmology and optometry practices, as well as single-specialty eye surgery centers. Today UVP supports a network
More news about: Waud Capital Partners
Sep 29, 2025, 02:00 ET Astellas Announces Top Management Personnel Change
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Sep 29, 2025, 01:01 ET Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
a global ophthalmology franchise." Paolo Cioccetti, CEO Italy, VISUfarma, added, "Combining with Lupin represents an exciting new chapter for VISUfarma. As part of Lupin's ophthalmology operations, we will build towards a global ophthalmology franchise
More news about: Lupin Limited
Sep 29, 2025, 00:45 ET Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
its strengths to build a global ophthalmology franchise." Paolo Cioccetti, CEO Italy, VISUfarma, added, "Combining with Lupin represents an exciting new chapter for VISUfarma. As part of Lupin's ophthalmology operations, we will build towards
More news about: Lupin Limited
Sep 26, 2025, 07:12 ET Deep EigenMatics Receives United States Patent for Inventing Breakthrough Artificial Intelligence Method for Protein Design and Drug Discovery
ligands for selected targets within its five therapeutic areas of interest: Cardiovascular-Renal-Metabolic, Oncology, Immunology, Neurology, and Ophthalmology. The company is in the earliest stages of discussions with large pharmaceutical companies regarding potential licensing and co-development partnership
More news about: Deep EigenMatics
Sep 25, 2025, 09:32 ET Paired assistance transforms healthcare in Xinjiang
relatively underdeveloped. Tang Yong, a specialist from Tianjin providing assistance in Xinjiang as director of the Ophthalmology Department at Hetian Prefecture People's Hospital, mentioned that his hospital is advancing collaborative research projects with hospitals in
More news about: Beijing Review
Sep 24, 2025, 10:59 ET ENCELTO Now Available Through OCLI Vision to Address Rare Retinal Disease, Announces Spectrum Vision Partners
CITY, N.Y., Sept. 24, 2025 /PRNewswire/ -- OCLI Vision, a leading ophthalmology practice managed by Spectrum Vision Partners, made medical history on September 22, 2025, by performing the first
More news about: Spectrum Vision Partners
Sep 24, 2025, 08:00 ET Tapping LATAM's Untapped Patient Pool for Ophthalmology Trials, Upcoming Webinar Hosted by Xtalks
as a powerful yet underutilized region — including in ophthalmology. Join Fortrea this World Sight Day for a dynamic webinar exploring how LATAM's unique healthcare landscape, patient population and site infrastructure can accelerate ophthalmology clinical trials and improve global trial equity.
More news about: Xtalks
Sep 23, 2025, 12:27 ET Children's Eye Foundation and American Association for Pediatric Ophthalmology and Strabismus: WHY VISION SCREENINGS SHOULD BE AT THE TOP OF YOUR BACK-TO-SCHOOL CHECKLIST
associate professor of ophthalmology at Ohio State University and is a member of the medical staff at Nationwide Children's Hospital. She is also a member of the American Academy of Ophthalmology and the American Association for Pediatric Ophthalmology and Strabismus (AAPOS).
More news about: Children's Eye Foundation and American Association for Pediatric Ophthalmology and Strabismus
Sep 22, 2025, 14:34 ET Cornea and Refractive Surgeon Dr. Talia Shoshany Joins OCLI Vision in Connecticut
Shoshany went on to earn her medical degree with honors from Harvard Medical School. She completed her ophthalmology residency at the prestigious Wills Eye Hospital in Philadelphia, where she was recognized with numerous
More news about: Spectrum Vision Partners
Sep 22, 2025, 08:00 ET Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Sep 18, 2025, 10:00 ET OCLI Vision Welcomes Dr. Anna Terrarosa, Oculoplastics Specialist, to Nassau County and Queens Locations This August
network. Prior to her fellowship, Dr. Terrarosa completed her ophthalmology residency at the New York University Grossman School of Medicine, where she also served as the Ophthalmology Department Representative on the NYU House Staff Patient Safety Council,
More news about: Spectrum Vision Partners
Sep 18, 2025, 06:45 ET Mallinckrodt Announces Publication of Findings on Treatment Patterns and Outcomes in Patients with Two Types of Arthritis Treated with Acthar® Gel (repository corticotropin injection)
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Sep 18, 2025, 00:00 ET Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported a clinical update on IBI324 (Ollin R&D code: OLN324).
More news about: Innovent Biologics
Sep 17, 2025, 15:56 ET Retina Specialist Dr. Eric Ruff Joins Buffalo Niagara Retina Associates | OCLI Vision
retinal procedures and patient-focused retinal care. A graduate of SUNY Downstate College of Medicine, Dr. Ruff completed his ophthalmology residency at Albany Medical College, where he served as Co-Chief Resident, and his internship at
More news about: Spectrum Vision Partners
Sep 17, 2025, 15:20 ET Dr. Collin Anderson to Join OCLI Vision in East Hanover and Morristown
Vision he served as the Chief Resident in Ophthalmology at SUNY Upstate Medical University. Dr. Anderson has contributed to the field through national presentations and peer-reviewed publications spanning ophthalmology, anesthesia, and neurology. He
More news about: Spectrum Vision Partners
Sep 17, 2025, 07:32 ET Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental,
More news about: Biocon Biologics
Sep 16, 2025, 15:06 ET Parker Waichman LLP Files Lawsuit on Behalf of Baltimore Resident Alleging Irreversible Eye Condition After Taking Ozempic
drug to NAION, a permanent condition that cuts off blood flow to the optic nerve and can result in blindness. A 2025 study in JAMA Ophthalmology reported multiple cases of optic nerve disorders among GLP-1 users, most with NAION-like symptoms. Separately,
More news about: Parker Waichman LLP
Sep 16, 2025, 09:00 ET ExSight Ventures Invests in RevOpsis Therapeutics to Advance Innovative Treatments for Blinding Eye Diseases
Sept. 16, 2025 /PRNewswire/ -- ExSight Ventures, a venture capital firm dedicated to investing in transformative ophthalmology innovations, today announced its investment in RevOpsis Therapeutics, a biotechnology company pioneering next-generation therapies for retinal
More news about: RevOpsis
Sep 16, 2025, 07:33 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Sep 16, 2025, 07:25 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions